Prof. Dr. med. Mascha Binder

Brandt, Anna, Schultheiss, Christoph, Klinghammer, Konrad, Schafhausen, Philippe, Busch, Chia-Jung, Blaurock, Markus, Hinke, Axel, Tometten, Mareike, Dietz, Andreas, Müller-Richter, Urs, Hahn, Dennis, Alt, Jürgen, Stein, Alexander, & Binder, Mascha. (2024). Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1283266

Diexer, Sophie, Klee, Bianca, Gottschick, Cornelia, Broda, Anja, Purschke, Oliver, Binder, Mascha, Gekle, Michael, Girndt, Matthias, Hoell, Jessica I., Moor, Irene, Sedding, Daniel, Rosendahl, Jonas, & Mikolajczyk, Rafael. (2024). Insights into early recovery from Long COVID—results from the German DigiHero Cohort. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-59122-3

Fischer, Claudia, Willscher, Edith, Paschold, Lisa, Gottschick, Cornelia, Klee, Bianca, Diexer, Sophie, Bosurgi, Lidia, Dutzmann, Jochen, Sedding, Daniel, Frese, Thomas, Girndt, Matthias, Hoell, Jessica I., Gekle, Michael, Addo, Marylyn M., Schulze zur Wiesch, Julian, Mikolajczyk, Rafael, Binder, Mascha, & Schultheiß, Christoph. (2024). SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition [Journal-article]. npj Vaccines, 9(1). https://doi.org/10.1038/s41541-024-00815-1

Glaser, Nadine, Diexer, Sophie, Klee, Bianca, Purschke, Oliver, Binder, Mascha, Frese, Thomas, Girndt, Matthias, Höll, Jessica, Moor, Irene, Rosendahl, Jonas, Gekle, Michael, Sedding, Daniel, Mikolajczyk, Rafael, & Gottschick, Cornelia. (2024). The contribution of SARS-CoV-2 to the burden of acute respiratory infections in winter season 2022/2023: results from the DigiHero study. International Journal of Infectious Diseases, 144. https://doi.org/10.1016/j.ijid.2024.107057

Klee, B., Diexer, S., Xu, C., Gottschick, C., Hartmann, C., Meyer-Schlinkmann, K. M., Kuhlmann, A., Rosendahl, J., Binder, M., Gekle, M., Girndt, M., Höll, J. I., Moor, I., Sedding, D., Moritz, S., Frese, T., & Mikolajczyk, R. (2024). Household transmission of Omicron variant of SARS-CoV-2 under conditions of hybrid immunity—a prospective study in Germany. Infection. https://doi.org/10.1007/s15010-024-02352-4

Märkl, Florian, Schultheiß, Christoph, Ali, Murtaza, Chen, Shih-Shih, Zintchenko, Marina, Egli, Lukas, Mietz, Juliane, Chijioke, Obinna, Paschold, Lisa, Spajic, Sebastijan, Holtermann, Anne, Dörr, Janina, Stock, Sophia, Zingg, Andreas, Läubli, Heinz, Piseddu, Ignazio, Anz, David, Minden, Marcus Dühren-von, Zhang, Tianjiao, et al. (2024). Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature Communications, 15. https://doi.org/10.1038/s41467-024-45378-w

Mohme, Malte, Schultheiß, Christoph, Piffko, Andras, Fitzek, Antonia, Paschold, Lisa, Thiele, Benjamin, Püschel, Klaus, Glatzel, Markus, Westphal, Manfred, Lamszus, Katrin, Matschke, Jakob, & Binder, Mascha. (2024). SARS-CoV-2-associated T-cell infiltration in the central nervous system [Journal-article]. Clinical and Translational Immunology, 13(2). https://doi.org/10.1002/cti2.1487

Padoan, Benedetta, Casar, Christian, Krause, Jenny, Schultheiss, Christoph, Baumdick, Martin E., Niehrs, Annika, Zecher, Britta F., Pujantell, Maria, Yuki, Yuko, Martin, Maureen, Remmerswaal, Ester B.M., Dekker, Tamara, van der Bom-Baylon, Nelly D., Noble, Janelle A., Carrington, Mary, Bemelman, Frederike J., van Lier, Rene A.W., Binder, Mascha, Gagliani, Nicola, et al. (2024). NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells. Cell Reports, 43. https://doi.org/10.1016/j.celrep.2024.114089

Diexer, S., Klee, B., Gottschick, C., Xu, C., Broda, A., Purschke, O., Binder, M., Frese, T., Girndt, M., Hoell, J. I., Moor, I., Gekle, M., & Mikolajczyk, R. (2023). Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. International Journal of Infectious Diseases, 136, 14–21. https://doi.org/10.1016/j.ijid.2023.08.019

Klee, B., Diexer, S., Sarajan, M. H., Glaser, N., Binder, M., Frese, T., Girndt, M., Sedding, D., Hoell, J. I., Moor, I., Gekle, M., Mikolajczyk, R., & Gottschick, C. (2023). Regional Differences in Uptake of Vaccination against COVID-19 and Influenza in Germany: Results from the DigiHero Cohort. Vaccines, 11(11). https://doi.org/10.3390/vaccines11111640

Mezger, N. C. S., Hämmerl, L., Griesel, M., Seraphin, T. P., Joko-Fru, Y. W., Feuchtner, J., Zietsman, A., Péko, J.-F., Tadesse, F., Buziba, N. G., Wabinga, H., Nyanchama, M., Chokunonga, E., Kéita, M., N’da, G., Lorenzoni, C. F., Akele-Akpo, M.-T., Mezger, J. M., Binder, M., et al. (2023). Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort. Oncologist, 28(11), E1017–E1030. https://doi.org/10.1093/oncolo/oyad157

Brioli, A., Gengenbach, L., Mancuso, K., Binder, M., Ernst, T., Heidel, F. H., Stauch, T., Zamagni, E., Hilgendorf, I., Hochhaus, A., Engelhardt, M., & von Lilienfeld-Toal, M. (2023). Pomalidomide combinations are a safe and effective option after daratumumab failure. Journal of Cancer Research and Clinical Oncology, 149(9), 6569–6574. https://doi.org/10.1007/s00432-023-04637-x

Jaeger, A., Gambheer, S. M. M., Sun, X., Chernyakov, D., Skorobohatko, O., Mack, T., Kissel, S., Pfeifer, D., Zeiser, R., Fisch, P., Andrieux, G., Bräuer-Hartmann, D., Bauer, M., Schulze, S., Follo, M., Boerries, M., von Bubnoff, N., Miething, C., Hidalgo, J. V., et al. (2023). Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood, 141(23), 2824–2840. https://doi.org/10.1182/blood.2022015653

Groß, E., Hilger, R.-A., Schümann, F. L., Bauer, M., Bouska, A., Rohde, C., Willscher, E., Lützkendorf, J., Müller, L. P., Edemir, B., Mueller, T., Herling, M., Binder, M., Wickenhauser, C., Iqbal, J., Posern, G., & Weber, T. (2023). SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. Cancers, 15(11). https://doi.org/10.3390/cancers15113043

Katzerke, C., Schaffrath, J., Lützkendorf, J., Janssen, M., Merbach, A.-K., Nerger, K., Binder, M., Baum, C., Lauer, K., Rohde, C., Willscher, E., Müller-Tidow, C., & Müller, L. P. (2023). Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome. Blood Advances, 7(12), 2811–2824. https://doi.org/10.1182/bloodadvances.2022008510

Gottschick, C., Diexer, S., Massag, J., Klee, B., Broda, A., Purschke, O., Binder, M., Sedding, D., Frese, T., Girndt, M., Hoell, J. I., Michl, P., Gekle, M., & Mikolajczyk, R. (2023). Mental health in Germany in the first weeks of the Russo-Ukrainian war. BJPsych Open, 9(3). https://doi.org/10.1192/bjo.2023.21

Schultheiß, C., Steinmann, S., Willscher, E., Paschold, L., Lohse, A. W., & Binder, M. (2023). Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis [Journal-article]. Hepatology Communications, 7(5). https://doi.org/10.1097/HC9.0000000000000123

Claaß, L. V., Mayr, P., Paschold, L., Weber, T., Terziev, D., Jehs, B., Brill, R., Dober, J., Märkl, B., Wickenhauser, C., Czapiewski, P., Trepel, M., Claus, R., & Binder, M. (2023). No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination. Cancer Medicine, 12(8), 9313–9321. https://doi.org/10.1002/cam4.5687

Brandt, Anna, Thiele, Benjamin, Schultheiß, Christoph, Daetwyler, Eveline, & Binder, Mascha. (2023). Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. Cancers, 15. https://doi.org/10.3390/cancers15072051

Marcinkevics, Ricards, Silva, Pamuditha N., Hankele, Anna-Katharina, Dörnte, Charlyn, Kadelka, Sarah, Csik, Katharina, Godbersen, Svenja, Goga, Algera, Hasenöhrl, Lynn, Hirschi, Pascale, Kabakci, Hasan, LaPierre, Mary P., Mayrhofer, Johanna, Title, Alexandra C., Shu, Xuan, Baiioud, Nouell, Bernal, Sandra, Dassisti, Laura, Saenz-de-Juano, Mara D., et al. (2023). Machine learning analysis of humoral and cellular responses to SARS-CoV-2 infection in young adults [Journal-article]. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1158905

Massag, J., Diexer, S., Klee, B., Costa, D., Gottschick, C., Broda, A., Purschke, O., Opel, N., Binder, M., Sedding, D., Frese, T., Girndt, M., Hoell, J., Moor, I., Rosendahl, J., Gekle, M., & Mikolajczyk, R. (2023). Anxiety, depressive symptoms, and distress over the course of the war in Ukraine in three federal states in Germany. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1167615

Paschold, Lisa, Gottschick, Cornelia, Langer, Susan, Klee, Bianca, Diexer, Sophie, Aksentijevich, Ivona, Schultheiß, Christoph, Purschke, Oliver, Riese, Peggy, Trittel, Stephanie, Haase, Roland, Dressler, Frank, Eberl, Wolfgang, Hübner, Johannes, Strowig, Till, Guzman, Carlos A., Mikolajczyk, Rafael, & Binder, Mascha. (2023). T cell repertoire breadth is associated with the number of acute respiratory infections in the LoewenKIDS birth cohort. Scientific Reports, 13. https://doi.org/10.1038/s41598-023-36144-x

Paschold, Lisa, Stein, Alexander, Thiele, Benjamin, Tintelnot, Joseph, Henkes, Svenja-Sibylla, Coith, Cornelia, Schultheiß, Christoph, Pantel, Klaus, Riethdorf, Sabine, & Binder, Mascha. (2023). First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial. Journal for ImmunoTherapy of Cancer, 11. https://doi.org/10.1136/jitc-2023-006678

Stein, Alexander, Thiele, Benjamin, & Binder, Mascha. (2023). Perioperative concepts for resectable adenocarcinomas of the stomach and gastroesophageal junction: Standard of Care and future developments. Tumor Diagnostik Und Therapie, 44(8), 540–544. https://doi.org/10.1055/a-2073-0206

Tintelnot, Joseph, Stein, Alexander, Al-Batran, Salah-Eddin, Ettrich, Thomas, Götze, Thorsten, Grün, Barbara, Haag, Georg Martin, Heuer, Vera, Hofheinz, Ralf-Dieter, Homann, Nils, Bröring, Tobias Sebastian, Cruz, Mariana Santos, Kurreck, Annika, Lorenzen, Sylvie, Moosmann, Nicolas, Müller, Christian, Schuler, Markus, Siegler, Gabriele, Binder, Mascha, & Gökkurt, Eray. (2023). Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321). Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1272175

Ellingsen, E. B., Bounova, G., Kerzeli, I., Anzar, I., Simnica, D., Aamdal, E., Guren, T., Clancy, T., Mezheyeuski, A., Inderberg, E. M., Mangsbo, S. M., Binder, M., Hovig, E., & Gaudernack, G. (2022). Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03624-z

Grimm, J., & Binder, M. (2022). Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome. Signal Transduction and Targeted Therapy, 7(1). https://doi.org/10.1038/s41392-022-01143-3

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., Celico, C., Falautano, M., Nonis, A., La Rosée, P., Binder, M., Fabbri, A., Ilariucci, F., Krampera, M., Roth, A., Hemmaway, C., Johnson, P. W., Linton, K. M., Pukrop, T., Gørløv, J. S., et al. (2022). Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 36(7), 1870–1878. https://doi.org/10.1038/s41375-022-01582-5

Jonas, H., Simnica, D., Bußmann, L., Zech, H., Doescher, J., Laban, S., Busch, C.-J., & Binder, M. (2022). Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN. Oral Oncology, 126. https://doi.org/10.1016/j.oraloncology.2022.105733

Jotschke, S., Schulze, S., Jaekel, N., Ludwig-Kraus, B., Engelmann, R., Kraus, F. B., Zahn, C., Nedlitz, N., Prange-Krex, G., Mohm, J., Peuser, B., Schwarz, M., Spohn, C., Behlendorf, T., Binder, M., Junghanss, C., Böttcher, S., & Al-Ali, H. K. (2022). Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). Cancers, 14(6). https://doi.org/10.3390/cancers14061544

Paschold, L., & Binder, M. (2022). Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer. Current Oncology, 29(3), 1430–1441. https://doi.org/10.3390/curroncol29030120

Schaffrath, J., Diederichs, T., Unverzagt, S., Wass, M., Gläser, U., Weber, T., Binder, M., Müller-Tidow, C., & Müller, L. P. (2022). Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 101(3), 681–691. https://doi.org/10.1007/s00277-021-04736-0

Grimm, J., Simnica, D., Jäkel, N., Paschold, L., Willscher, E., Schulze, S., Dierks, C., Al-Ali, H. K., & Binder, M. (2022). Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients. Blood Cancer Journal, 12(1). https://doi.org/10.1038/s41408-022-00615-7

van Wilpe, S., Simnica, D., Slootbeek, P., van Ee, T., Pamidimarri Naga, S., Gorris, M. A. J., van der Woude, L. L., Sultan, S., Koornstra, R. H. T., van Oort, I. M., Gerritsen, W. R., Kroeze, L. I., Simons, M., van Leenders, G. J. L. H., Binder, M., de Vries, I. J. M., & Mehra, N. (2022). Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2094133

Schümann, F. L., Groß, E., Bauer, M., Rohde, C., Sandmann, S., Terziev, D., Müller, L. P., Posern, G., Wienke, A., Fend, F., Hansmann, M.-L., Klapper, W., Rosenwald, A., Stein, H., Dugas, M., Müller-Tidow, C., Wickenhauser, C., Binder, M., & Weber, T. (2021). Divergent effects of ezh1 and ezh2 protein expression on the prognosis of patients with t-cell lymphomas. Biomedicines, 9(12). https://doi.org/10.3390/biomedicines9121842

Paschold, L., Willscher, E., Bein, J., Vornanen, M., Eichenauer, D. A., Simnica, D., Thiele, B., Wickenhauser, C., Rosenwald, A., Bernd, H.-W., Klapper, W., Feller, A. C., Ott, G., Fend, F., Hartmann, S., & Binder, M. (2021). Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica, 106(10), 2654–2666. https://doi.org/10.3324/haematol.2021.278427

Schümann, F. L., Bauer, M., Groß, E., Terziev, D., Wienke, A., Wickenhauser, C., Binder, M., & Weber, T. (2021). Rbmx protein expression in t-cell lymphomas predicts chemotherapy response and prognosis. Cancers, 13(19). https://doi.org/10.3390/cancers13194788

Bußmann, L., Hoffer, K., von Bargen, C. M., Droste, C., Lange, T., Kemmling, J., Schröder-Schwarz, J., Vu, A. T., Akingunsade, L., Nollau, P., Rangarajan, S., de Wijn, R., Oetting, A., Müller, C., Böckelmann, L. C., Zech, H. B., Berger, J. C., Möckelmann, N., Busch, C.-J., et al. (2021). Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets. International Journal of Cancer, 149(5), 1166–1180. https://doi.org/10.1002/ijc.33606

Thiele, B., Binder, M., Schliffke, S., Frenzel, C., Dierlamm, J., Wass, M., Weisel, K. C., Bokemeyer, C., & Janjetovic, S. (2021). Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. Oncology Research and Treatment, 44(7), 375–380. https://doi.org/10.1159/000517531

Wass, M., Göllner, S., Besenbeck, B., Schlenk, R. F., Mundmann, P., Göthert, J. R., Noppeney, R., Schliemann, C., Mikesch, J.-H., Lenz, G., Dugas, M., Wermke, M., Röllig, C., Bornhäuser, M., Serve, H., Platzbecker, U., Foerster, K. I., Burhenne, J., Haefeli, W. E., et al. (2021). A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia, 35(3), 701–711. https://doi.org/10.1038/s41375-020-0892-z

Porritt, R. A., Binek, A., Paschold, L., Rivas, M. N., McArdle, A., Yonker, L. M., Alter, G., Chandnani, H. K., Lopez, M., Fasano, A., Van Eyk, J. E., Binder, M., & Arditi, M. (2021). The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. Journal of Clinical Investigation, 131(20). https://doi.org/10.1172/jci151520

Zech, H. B., Moeckelmann, N., Boettcher, A., Muenscher, A., Binder, M., Vettorazzi, E., Bokemeyer, C., Schafhausen, P., Betz, C. S., & Busch, C.-J. (2020). Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. Future Oncology, 16(36), 3035–3043. https://doi.org/10.2217/fon-2020-0595

Cheng, M. H., Zhang, S., Porritt, R. A., Rivas, M. N., Paschold, L., Willscher, E., Binder, M., Arditi, M., & Bahar, I. (2020). Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proceedings of the National Academy of Sciences of the United States of America, 117(41), 25254–25262. https://doi.org/10.1073/pnas.2010722117

Simnica, D., Ittrich, H., Bockemeyer, C., Stein, A., & Binder, M. (2020). Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.540030

Mezger, N. C. S., Feuchtner, J., Griesel, M., Hämmerl, L., Seraphin, T. P., Zietsman, A., Péko, J.-F., Tadesse, F., Buziba, N. G., Wabinga, H., Nyanchama, M., Borok, M. Z., Kéita, M., N’da, G., Lorenzoni, C. F., Akele-Akpo, M.-T., Gottschick, C., Binder, M., Mezger, J., et al. (2020). Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa. British Journal of Haematology, 190(2), 209–221. https://doi.org/10.1111/bjh.16575

Terziev, D., Bauer, M., Paschold, L., Wickenhauser, C., Wienke, A., Binder, M., Müller, L. P., & Weber, T. (2020). Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma. PLoS ONE, 15(7 July). https://doi.org/10.1371/journal.pone.0235786

Mohme, M., Maire, C. L., Geumann, U., Schliffke, S., Duhrsen, L., Fita, K., Akyuz, N., Binder, M., Westphal, M., Guenther, C., Lamszus, K., Hermann, F. G., & Schmidt, N. O. (2020). Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma. Clinical Cancer Research, 26(11), 2626–2639. https://doi.org/10.1158/1078-0432.ccr-19-0803

Tintelnot, J., Goekkurt, E., Binder, M., Thuss-Patience, P., Lorenzen, S., Knorrenschild, J. R., Kretzschmar, A., Ettrich, T., Lindig, U., Jacobasch, L., Pink, D., Al-Batran, S.-E., Hinke, A., Hegewisch-Becker, S., Nilsson, S., Bokemeyer, C., & Stein, A. (2020). Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer, 20(1). https://doi.org/10.1186/s12885-020-06958-3

Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., Fehse, B., Röckendorf, J. L., Schmid, J., Albrecht, B., Pinnschmidt, H., Ayuk, F., Kröger, N., Binder, M., Schuch, G., et al. (2020). Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics, 10(6), 2645–2658. https://doi.org/10.7150/thno.38533

Simnica, D., Smits, M., Willscher, E., Fanchi, L. F., Kloots, I. S. H., van Oort, I., Gerritsen, W., Mehra, N., & Binder, M. (2020). Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 4, 1374–1385. https://doi.org/10.1200/po.20.00209

Gomes de Castro, M. A., Wildhagen, H., Sograte-Idrissi, S., Hitzing, C., Binder, M., Trepel, M., Engels, N., & Opazo, F. (2019). Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-08677-1

Janjetovic, S., Asemissen, A. M., Dicker, F., Binder, M., Dierlamm, J., Bokemeyer, C., & Schafhausen, P. (2019). Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. Tumori, 105(6), NP8–NP11. https://doi.org/10.1177/0300891619839473

Simnica, D., Akyüz, N., Schliffke, S., Mohme, M., v.Wenserski, L., Mährle, T., Fanchi, L. F., Lamszus, K., & Binder, M. (2019). T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. OncoImmunology, 8(11). https://doi.org/10.1080/2162402x.2019.1644110

von Felden, J., Alric, L., Pischke, S., Aitken, C., Schlabe, S., Spengler, U., Giordani, M. T., Schnitzler, P., Bettinger, D., Thimme, R., Xhaard, A., Binder, M., Ayuk, F., Lohse, A. W., Cornelissen, J.J., de Man, R. A., & Mallet, V. (2019). The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. Journal of Hepatology, 71(3), 465–472. https://doi.org/10.1016/j.jhep.2019.04.022

Schliffke, S., Carambia, A., Akyüz, N., Thiele, B., Herkel, J., & Binder, M. (2019). T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model. Journal of Neuroimmunology, 332, 49–56. https://doi.org/10.1016/j.jneuroim.2019.03.014

Mährle, T., Akyüz, N., Fuchs, P., Bonzanni, N., Simnica, D., Germing, U., Asemissen, A. M., Jann, J. C., Nolte, F., Hofmann, W.-K., Nowak, D., & Binder, M. (2019). Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide. Haematologica, 104(7), 1355–1364. https://doi.org/10.3324/haematol.2018.208223

Brandt, A., Matschke, J., Fehrle, W., von Wenserski, L., Bokemeyer, C., Illerhaus, G., & Binder, M. (2019). A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. Leukemia and Lymphoma, 60(2), 334–340. https://doi.org/10.1080/10428194.2018.1482538

Rossi, A., Voigtlaender, M., Klose, H., Schlüter, H., Schön, G., Loges, S., Paolini, M., Bokemeyer, C., Reck, M., Tarro, G., & Binder, M. (2019). High aldehyde dehydrogenase levels are detectable in the serum of patients with lung cancer and may be exploited as screening biomarkers. Journal of Oncology, 2019. https://doi.org/10.1155/2019/8970645

Schieferdecker, A., Binder, M., Weisel, K., & Bokemeyer, C. (2019). Monoclonal Gammopathy of Unknown Significance - A Common Incidental Finding: What is to be thought of? What has to be done? Monoklonale Gammopathie unklarer Signifikanz - ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun? Deutsche Medizinische Wochenschrift, 144(14), 982–989. https://doi.org/10.1055/a-0832-3393

Caers, J., Garderet, L., Kortüm, K. M., O’dwyer, M. E., van de Donk, N. W. C. J., Binder, M., Dold, S. M., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, M. A., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M., et al. (2018). European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when. Haematologica, 103(11), 1772–1784. https://doi.org/10.3324/haematol.2018.189159

Mohme, M., Schliffke, S., Maire, C. L., Runger, A., Glau, L., Mende, K. C., Matschke, J., Gehbauer, C., Akyuz, N., Zapf, S., Holz, M., Schaper, M., Martens, T., Schmidt, N. O., Peine, S., Westphal, M., Binder, M., Tolosa, E., & Lamszus, K. (2018). Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. Clinical Cancer Research, 24(17), 4187–4200. https://doi.org/10.1158/1078-0432.ccr-17-2617

Schliffke, S., Buhs, S., Bolz, S., Gerull, H., von Wenserski, L., Riecken, K., Fehse, B., Nollau, P., & Binder, M. (2018). The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. Blood, 131(15), 1755–1758. https://doi.org/10.1182/blood-2017-06-788166

Schliffke, S., Sivina, M., Kim, E., von Wenserski, L., Thiele, B., Akyüz, N., Falker-Gieske, C., Statovci, D., Oberle, A., Thenhausen, T., Krohn-Grimberghe, A., Bokemeyer, C., Jain, N., Estrov, Z., Ferrajoli, A., Wierda, W., Keating, M., Burger, J. A., & Binder, M. (2018). Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. OncoImmunology, 7(4). https://doi.org/10.1080/2162402x.2017.1417720

Bera, T.K., Abe, Y., Ise, T., Oberle, A., Gallardo, D., Liu, X.-F., Nagata, S., Binder, M., & Pastan, I. (2018). Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients. Leukemia, 32(2), 539–572. https://doi.org/10.1038/leu.2017.315

Fumey, W., Koenigsdorf, J., Kunick, V., Menzel, S., Schütze, K., Unger, M., Schriewer, L., Haag, F., Adam, G., Oberle, A., Binder, M., Fliegert, R., Guse, A., Zhao, Y. J., Lee, H. C., Malavasi, F., Goldbaum, F., Van Hegelsom, R., Stortelers, C., et al. (2017). Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-14112-6

Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, & Illerhaus G. (2017). High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia, 31(12), 2623–2629. https://doi.org/10.1038/leu.2017.170

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosée, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Sønderskov Gørløv, J., et al. (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. The Lancet Haematology, 4(11), e510–e523. https://doi.org/10.1016/s2352-3026(17)30174-6

Fichtner, M., Dreyling, M., Binder, M., & Trepel, M. (2017). The role of B cell antigen receptors in mantle cell lymphoma. Journal of Hematology and Oncology, 10(1). https://doi.org/10.1186/s13045-017-0533-9

Oberle, A., Brandt, A., Alawi, M., Langebrake, C., Janjetovic, S., Wolschke, C., Schütze, K., Bannas, P., Kröger, N., Koch-Nolte, F., Bokemeyer, C., & Binder, M. (2017). Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica, 102(9), 368–370. https://doi.org/10.3324/haematol.2017.169235

Körbelin, J., Hunger, A., Alawi, M., Sieber, T., Binder, M., & Trepel, M. (2017). Optimization of design and production strategies for novel adeno-associated viral display peptide libraries. Gene Therapy, 24(8), 470–481. https://doi.org/10.1038/gt.2017.51

Akyüz, N., Brandt, A., Stein, A., Schliffke, S., Mährle, T., Quidde, J., Goekkurt, E., Loges, S., Haalck, T., Ford, C. T., Asemissen, A. M., Thiele, B., Radloff, J., Thenhausen, T., Krohn-Grimberghe, A., Bokemeyer, C., & Binder, M. (2017). T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. International Journal of Cancer, 140(11), 2535–2544. https://doi.org/10.1002/ijc.30549

Braig, F., Kriegs, M., Voigtlaender, M., Habel, B., Grob, T., Biskup, K., Blanchard, V., Sack, M., Thalhammer, A., Batalla, I. B., Braren, I., Laban, S., Danielczyk, A., Goletz, S., Jakubowicz, E., Märkl, B., Trepel, M., Knecht, R., Riecken, K., et al. (2017). Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism. Cancer Research, 77(5), 1188–1199. https://doi.org/10.1158/0008-5472.can-16-0754

Braig, F., Brandt, A., Goebeler, M., Tony, H.-P., Kurze, A.-K., Nollau, P., Bumm, T., Böttcher, S., Bargou, R. C., & Binder, M. (2017). Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood, 129(1), 100–104. https://doi.org/10.1182/blood-2016-05-718395

Oberle, A., Brandt, A., Voigtlaender, M., Thiele, B., Radloff, J., Schulenkorf, A., Alawi, M., Akyüz, N., März, M., Ford, C. T., Krohn-Grimberghe, A., & Binder, M. (2017). Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica, 102(6), 1105–1111. https://doi.org/10.3324/haematol.2016.161414

Rossi, A., Voigtlaender, M., Janjetovic, S., Thiele, B., Alawi, M., März, M., Brandt, A., Hansen, T., Radloff, J., Schön, G., Hegenbart, U., Schönland, S., Langer, C., Bokemeyer, C., & Binder, M. (2017). Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood Cancer Journal, 7(2). https://doi.org/10.1038/bcj.2017.19

Schliffke, S., Akyüz, N., Ford, C.T., Mährle, T., Thenhausen, T., Krohn-Grimberghe, A., Knop, S., Bokemeyer, C., & Binder, M. (2016). Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. Leukemia, 30(11), 2232–2234. https://doi.org/10.1038/leu.2016.157

Shumilov, E., Wulf, G., Ströbel, P., Hasenkamp, J., Hellige, N., Bleckmann, A., Haase, D., Braulke, F., Jung, W., Schanz, J., Binder, M., Trümper, L., & Bacher, U. (2016). Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. Leukemia and Lymphoma, 57(10), 2476–2480. https://doi.org/10.3109/10428194.2016.1151510

Bacher, U., & Binder, M. (2016). Modifying therapy in patients with advanced Hodgkin’s lymphoma by integrating early metabolic response by interim PET-CT. Annals of Translational Medicine, 4. https://doi.org/10.21037/atm.2016.10.20

Maurer, C., Pflug, N., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A.-M., Eichhorst, B., Kreuzer, K.-A., Fischer, N., Tausch, E., Stilgenbauer, S., Böttcher, S., Döhner, H., Kneba, M., Dreyling, M., Binder, M., et al. (2016). Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. European Journal of Haematology, 97(3), 253–260. https://doi.org/10.1111/ejh.12714

Schieferdecker, A., Oberle, A., Thiele, B., Hofmann, F., Göthel, M., Miethe, S., Hust, M., Braig, F., Voigt, M., Von Pein, U.-M., Koch-Nolte, F., Haag, F., Alawi, M., Indenbirken, D., Grundhoff, A., Bokemeyer, C., Bacher, U., Kröger, N., & Binder, M. (2016). A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma. Blood, 127(25), 3202–3214. https://doi.org/10.1182/blood-2015-10-676536

Alsdorf, W. H., Schmitz, M., Schieferdecker, A., Dierlamm, J., Bokemeyer, C., & Binder, M. (2016). Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature. Journal of Oncology Pharmacy Practice, 22(3), 523–527. https://doi.org/10.1177/1078155214562268

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Torri, V., Fox, C. P., Rosée, P. L., Schorb, E., Ambrosetti, A., Roth, A., Hemmaway, C., Ferrari, A., Linton, K. M., Rudà, R., Binder, M., Pukrop, T., Balzarotti, M., et al. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet Haematology, 3(5), e217–e227. https://doi.org/10.1016/s2352-3026(16)00036-3

Braig, F., Voigtlaender, M., Schieferdecker, A., Busch, C.-J., Laban, S., Grob, T., Kriegs, M., Knecht, R., Bokemeyer, C., & Binder, M. (2016). Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget, 7(28), 42988–42995. https://doi.org/10.18632/oncotarget.8943

Fichtner, M., Spies, E., Seismann, H., Riecken, K., Engels, N., Gösch, B., Dierlamm, J., Gerull, H., Nollau, P., Klapper, W., Dreyling, M., Binder, M., & Trepel, M. (2016). Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. Haematologica, 101(9), e378–e381. https://doi.org/10.3324/haematol.2016.141929

Kriegs, M., Kasten-Pisula, U., Riepen, B., Hoffer, K., Struve, N., Myllynen, L., Braig, F., Binder, M., Rieckmann, T., Grénman, R., Petersen, C., Dikomey, E., & Rothkamm, K. (2016). Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests. Oncotarget, 7(29), 45122–45133. https://doi.org/10.18632/oncotarget.9161

Brandt, Anna, & Binder, Mascha. (2015). The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies: Author’s reply. Leukemia and Lymphoma, 56(12). https://doi.org/10.3109/10428194.2015.1050667

Spies, E., Fichtner, M., Müller, F., Krasemann, S., Illerhaus, G., Glatzel, M., Binder, M., & Trepel, M. (2015). Comment on “primary central nervous system (CNS) lymphoma B cell receptors recognize CNS proteins”. Journal of Immunology, 195(10), 4549–4550. https://doi.org/10.4049/jimmunol.1501964

Voigtlaender, M., Vogler, B., Trepel, M., Panse, J., Jung, R., Bokemeyer, C., Bacher, U., & Binder, M. (2015). Hospital population screening reveals overrepresentation of CD5− monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type. Annals of Hematology, 94(9), 1559–1565. https://doi.org/10.1007/s00277-015-2409-9

Waizenegger, J.S., Ben-Batalla, I., Weinhold, N., Meissner, T., Wroblewski, M., Janning, M., Riecken, K., Binder, M., Atanackovic, D., Taipaleenmaeki, H., Schewe, D., Sawall, S., Gensch, V., Cubas-Cordova, M., Seckinger, A., Fiedler, W., Hesse, E., Kröger, N., Fehse, B., et al. (2015). Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia, 29(3), 696–704. https://doi.org/10.1038/leu.2014.236

Flammiger, Anna, Bacher, Ulrike, Christopeit, Maximilian, Horn, Christiane, Rühlmann, Elke, Kluge, Katrin, Vettorazzi, Eik, Bokemeyer, Carsten, & Binder, Mascha. (2015). Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance. Leukemia and Lymphoma, 56(3), 639–644. https://doi.org/10.3109/10428194.2014.926347

Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., Grob, T., Alawi, M., Indenbirken, D., Kriegs, M., Engel, E., Vanhoefer, U., Grundhoff, A., Loges, S., Riecken, K., Fehse, B., Bokemeyer, C., & Binder, M. (2015). Epidermal growth factor receptor mutation mediates crossresistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035–12047. https://doi.org/10.18632/oncotarget.3574

Yousef, S., Kovacsovics-Bankowski, M., Salama, M. E., Bhardwaj, N., Steinbach, M., Langemo, A., Kovacsovics, T., Marvin, J., Binder, M., Panse, J., Kröger, N., Luetkens, T., & Atanackovic, D. (2015). CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Human Vaccines and Immunotherapeutics, 11(7), 1606–1611. https://doi.org/10.1080/21645515.2015.1046658

Yousef, S., Marvin, J., Steinbach, M., Langemo, A., Kovacsovics, T., Binder, M., Kröger, N., Luetkens, T., & Atanackovic, D. (2015). Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer Journal, 5(3). https://doi.org/10.1038/bcj.2015.7

Rissiek, Anne, Schulze, Christian, Bacher, Ulrike, Schieferdecker, Aneta, Thiele, Benjamin, Jacholkowski, Anita, Flammiger, Anna, Horn, Christiane, Haag, Friedrich, Tiegs, Gisa, Zirlik, Katja, Trepel, Martin, Tolosa, Eva, & Binder, Mascha. (2014). Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia. International Journal of Cancer, 135(10), 2370–2379. https://doi.org/10.1002/ijc.28884

Thiele, B., Kloster, M., Alawi, M., Indenbirken, D., Trepel, M., Grundhoff, A., & Binder, M. (2014). Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma. Blood, 123(23), 3618–3621. https://doi.org/10.1182/blood-2014-02-556746

Binder, M., & Bacher, U. (2014). The role of CD81 for plasma cell dyscrasias. Leukemia Research, 38(3), 292–293. https://doi.org/10.1016/j.leukres.2013.12.026

Schieferdecker, A., Voigt, M., Riecken, K., Braig, F., Schinke, T., Loges, S., Bokemeyer, C., Fehse, B., & Binder, M. (2014). Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget, 5(16), 6647–6653. https://doi.org/10.18632/oncotarget.2160

Christopeit, M., Heiland, A., Binder, M., Zabelina, T., Ayuk, F., Horn, C., Haferlach, T., Bokemeyer, C., Kröger, N., & Bacher, U. (2013). Impact of physiological BM CD10 + CD19 + B-cell precursors (haematogones) in the post-transplant period in patients with AML. Bone Marrow Transplantation, 48(9), 1257–1259. https://doi.org/10.1038/bmt.2013.34

Oyekunle, A., Zander, A. R., Binder, M., Ayuk, F., Zabelina, T., Christopeit, M., Stübig, T., Alchalby, H., Schafhausen, P., Lellek, H., Wolschke, C., Müller, I., Bacher, U., & Kröger, N. (2013). Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Annals of Hematology, 92(4), 487–496. https://doi.org/10.1007/s00277-012-1650-8

Christopeit, M., Ocheni, S., Haferlach, T., Miersch, K., Zabelina, T., Klyuchnikov, E., Binder, M., Ayuk, F., Schafhausen, P., Zander, A.R., Bokemeyer, C., Kröger, N., & Bacher, U. (2013). Evaluation of BM cytomorphology after allo-SCT in patients with MDS. Bone Marrow Transplantation, 48(3), 465–466. https://doi.org/10.1038/bmt.2012.161